Long­time Zymeworks CEO, co-founder Tehrani hits the ex­it in fa­vor of se­r­i­al biotech en­tre­pre­neur

Af­ter a down year, bio­phar­ma writ large is look­ing for a breath of fresh air — and now the winds of change have hit on­col­o­gy bis­pecifics play­er Zymeworks.

Ali Tehrani, a co-founder of Zymeworks who has been the biotech’s CEO since 2003, has re­signed from his po­si­tion and will be re­placed by Ken Gal­braith, a se­r­i­al biotech en­tre­pre­neur and for­mer board mem­ber, the com­pa­ny said Wednes­day.

Tehrani will take on an ad­vi­so­ry role with the com­pa­ny once his tenure for­mal­ly ends Feb. 1 to help aid in the tran­si­tion for Gal­braith’s lead­er­ship turn. Mean­while, board chair Lota Zoth will be moved in­to an in­de­pen­dent di­rec­tor role in con­junc­tion with the shake­up.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER